Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that there will be almost 108 million prevalent cases of nicotine and alcohol addiction in 2015; however, only 12% of the cases will be prescription drug-treated. According to a new Pharmacor report entitled Addiction Disorders, the nicotine and alcohol addiction segments accounted for approximately 54% of the total addiction market in 2005, but they will account for roughly 79% of the total addiction market in 2015. The launch of new therapies and increases in diagnosis and drug-treatment rates, especially for nicotine addiction, will drive this growth.

New launches that will drive the addiction drug market include those of Pfizer's Chantix/Champix for smoking cessation, Nabi Biopharmaceuticals' NicVAX for nicotine addiction, and Alkermes/Cephalon's high-priced, once- monthly, injectable Vivitrol for alcohol dependence.

"The launch of Chantix/Champix in the United States and Europe in 2006 will move patients from over-the-counter nicotine replacement therapies to the prescription drug market, driving growth in these regions," said Amy Jassen, Ph.D., analyst at Decision Resources. "The arrival of NicVAX in the United States and Europe in 2010 and 2011, respectively, will increase overall prescription volume thanks to higher use of combination therapy. You can expect Vivitrol to take patient share from less-expensive drugs such as oral naltrexone and disulfiram because of its ability to increase compliance."

Addiction Disorders covers four addiction disorder markets: nicotine, alcohol, opioid, and psychostimulant addictions.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

  All company, brand, or product names contained in this document may be      trademarks or registered trademarks of their respective holders.    For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, or emarshall@dresources.com

Implantable Cardioverter Defibrillator Market Rebounding in Q4 2006

View Now